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Abstract
Purpose: Constitutively decreased TGFBR1 allelic expression is emerging as a potent modifier of colorectal cancer risk 
in mice and humans. This phenotype was first observed in mice, then in lymphoblastoid cell lines from patients with 
microsatellite stable colorectal tumors.
Patients and Methods: We assessed the frequency of constitutively decreased TGFBR1 allelic expression and 
association with SNPs covering the TGFBR1 locus using RNA and DNA extracted from the peripheral blood lymphocytes 
of 118 consecutive patients with biopsy-proven adenocarcinoma of the colon or the rectum.
Results: We found that 11(9.3%) of 118 patients exhibited decreased TGFBR1 allelic expression (TGFBR1 ASE). TGFBR1 
ASE was strongly associated with three SNPs in linkage disequilibrium with each other: rs7034462 (p = 7.2 × 10-4), 
TGFBR1*6A (p = 1.6 × 10-4) and rs11568785 (p = 1.4 × 10-4).
Conclusion: These results confirm the high prevalence of constitutively decreased TGFBR1 allelic expression among 
patients with colorectal cancer. The association of this phenotype with TGFBR1*6A, rs7034462 and rs1156875 suggests 
an association between TGFBR1 SNPs and colorectal cancer, which warrants additional studies.
Introduction
Clues regarding important genetic targets in colorectal
cancer have come from the study of two hereditary neo-
plastic syndromes: Familial Adenomatous Polyposis
(FAP) and Lynch syndrome, formerly named hereditary
non-polyposis colorectal cancer (HNPCC). Although the
genetic mechanisms underlying FAP and Lynch syn-
drome are well-understood, they only account for
approximately 0.2% and 2% of all colorectal cancers,
respectively. Inherited variants of the MYH  gene have
been shown to cause MYH-associated polyposis and are
thought to account for an additional 1% of all colorectal
cancers. Germline mutations of the STK11 gene underlie
the Peutz-Jeghers syndrome, and mutations of SMAD4
and BMPR1A cause juvenile polyposis. Collectively, these
syndromes account for 3 to 6% of all colorectal can-
cers[1].
Much of the remaining familial colorectal cancers and a
large proportion of sporadic cases are likely due to low-
penetrance mutations, i.e. mutations that have low fre-
quency of association with a specific phenotype[2]. Sev-
eral recent genome-wide association studies have
identified ten additional low penetrance susceptibility
alleles including BMP2[3],  BMP4[3] and SMAD7[3,4],
which all belong to the Transforming Growth Factor Beta
(TGF-β) superfamily of growth factors. These findings
provide strong support for the notion that the TGF-β sig-
naling pathway is implicated in colorectal cancer suscep-
tibility[5].
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We have previously mapped TGFBR1 to 9q22[6], and
our search for TGFBR1 tumor-specific mutations led us
to the discovery of a polymorphic allele of the type I
receptor, TGFBR1*6A (6A)[6]. This allele has a deletion
of three alanines within a 9-alanine stretch of TGFBR1
signal sequence, which results in decreased TGFBR1-
mediated signaling[7,8]. The fact that a significantly
higher 6A allelic frequency was found among patients
with a diagnosis of cancer than among healthy controls
prompted us to postulate that 6A may act functionally as
a tumor susceptibility allele[6]. Over the past few years,
some studies have confirmed an association between 6A
and cancer, but others have failed to establish any correla-
tion. A combined analysis of 17 case control studies that
included more than 13,000 cases and controls showed
that 6A allelic frequency was 44% higher among all can-
cer cases (0.082) than among controls (0.057) (p <
0.0001)[9]. The first combined analysis of the six studies
assessing 6A in colon cancer cases and controls indicated
that 6A carriers are at increased risk of developing col-
orectal cancer (O.R. 1.20, 95% CI 1.01-1.43)[10], but a
large case control study performed in Sweden did not
confirm this association (O.R. 1.13, 95% CI 0.98-
1.30)[11].
To test the hypothesis that constitutively decreased
TGFBR1 signaling modifies colorectal cancer risk, we
developed a novel mouse model of Tgfbr1 haploinsuffi-
ciency[12]. We crossed Tgfbr1  haploinsufficient mice
with  ApcMin/+  mice, one of the most commonly used
models of colorectal cancer, and found that constitutively
decreased Tgfbr1 signaling is a potent modifier of col-
orectal cancer risk[12]. These animal findings prompted
validation in patients with colorectal cancer. We chose
patients with microsatellite instability (MSI) negative col-
orectal cancer in order to exclude most patients with
somatically acquired TGFBR2  mutations, a common
finding in MSI-positive colorectal cancer[13]. This led to
the identification of two novel haplotypes associated with
decreased  TGFBR1  allelic expression and markedly
increased risk of colorectal cancer[14].
A recent report suggests that the TGFBR1 ASE pheno-
type is non-existent in patients with sporadic colorectal
cancer[15]. We undertook this study to assess whether
this is indeed the case, and to establish the frequency of
this novel phenotype in unselected, consecutively
recruited patients with colorectal cancer. The second goal
of this study was to determine the association of constitu-
tively decreased TGFBR1 allelic expression with haplo-
type tagging SNPs at the TGFBR1 locus. Our findings
confirm our original discovery of a high frequency of
constitutively decreased TGFBR1 allelic expression in
patients with colorectal cancer. They further establish its
association with TGFBR1*6A as well as two additional
haplotype tagging SNPs.
Methods
Patients
The series of colorectal cancer cases from Northwestern
University Medical and Surgical Clinics in Chicago have
been previously described [16]. They were enrolled as
part of IRB-approved protocols. Briefly, consecutive cases
with a biopsy-confirmed diagnosis of colorectal adeno-
carcinoma were recruited from the medical and surgical
oncology clinics affiliated with the Northwestern Medical
Faculty Foundation and U.S. Oncology during the years
2000 and 2006. RNA was only available for 118 of the 199
colorectal cases because of either a shortage of blood
RNA kits during part of the study or poor quality of the
extracted RNA.
DNA/RNA extraction and cDNA synthesis
DNA was extracted from whole blood samples using the
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA)
and was stored at -20°C until use for genotyping. RNA
was extracted from whole blood samples using the Pax-
gene Blood RNA Kit (Qiagen, Valencia, CA) prior to
reverse transcription with Taqman® Reverse Transcrip-
tion Reagents (Applied Biosystems, Foster City, CA).
Assessment of constitutively decreased TGFBR1 allelic 
expression
We used the methods described in our recent report
identifying constitutively decreased TGFBR1  allelic
expression in humans[14]. Briefly, germline DNA from all
patients with available DNA and RNA was genotyped for
the following four 3'-UTR SNPs: rs334348, rs334349,
rs1590 and rs7871490. The ratio of the two alleles in the
cDNA of the transcript was normalized with the ratio of
the two alleles in genomic DNA, applying the following
formula: cDNA (peak area common allele/peak area rare
allele) divided by gDNA (peak area common allele/peak
area rare allele). Each SNP was assayed with two indepen-
dent cDNA preparations, each in duplicate so that the
ASE was calculated as the average of 4 different ratios.
The diagnostic criteria for the TGFBR1 ASE phenotype
were the same as in our prior report, i.e. a ratio of cDNA/
gDNA either ≥ 1.5 or ≤ 0.67[14].
Selection of SNPs
Using phase II HapMap data for the HapMap European
(CEU) sample for TGFBR1, we selected 18 tag SNPs in
addition to TGFBR1*6A and genotyped the 19 variants in
all colorectal cancer cases. The tag SNPs were designed
to give pairwise r2 > 0.8 for all common SNPs in the
TGFBR1 region. A check using release 22 (April 2007) of
the HapMap Phase II data showed that this pairwise r 2
value was achieved for 57 of 58 common SNPs identified
in HapMap Phase II. The remaining common SNP was
tagged successfully (r2 > 0.8) using a haplotype of two ofPasche et al. Journal of Experimental & Clinical Cancer Research 2010, 29:57
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the tag SNPs. The mean r2 for the 58 SNPs was 0.967 indi-
cating excellent coverage of this region with our 18 tag
SNPs.
Statistical analyses
We used standard chi-square tests to assess the signifi-
cance of allele frequency differences between ASE indi-
viduals (>1.5 or <0.67; N = 11) and the remainder of the
cohort.
Results
Frequency of the TGFBR1 ASE phenotype
In this cross sectional study of 118 consecutively-
recruited patients with colorectal cancer 74 (62.7%) indi-
viduals were heterozygous for informative TGFBR1
SNPs. Eleven (9.3%) patients had evidence of constitu-
tively decreased TGFBR1 allelic expression, i.e. a ratio of
cDNA/gDNA either ≥ 1.5 or ≤ 0.67[14]. Median age at
diagnosis was 60 years in subjects with TGFBR1 ASE and
in those without and the sex distribution was similar as
well (Table 1). The frequency of constitutively decreased
TGFBR1 allelic expression among Caucasian patients was
10.2% (10/98)and 7.1% (1/14) in the African-American
population. None of the patients with self-described His-
panic (3) or Asian (3) ethnicity had decreased TGFBR1
allelic expression. Fifty-five percent of the patients with
decreased TGFBR1 allelic expression had a primary colon
cancer. This was similar to the 66% with primary colon
cancer in patients with normal TGFBR1 allelic expression
(p = 0.507; Fisher's Exact Test). The stage at diagnosis was
equivalent in both groups with only 9% presenting with
stage I disease and 27% of those with normal TGFBR1
allelic expression having stage IV disease, similar to the
3 6 %  i n  t h o s e  p a t i e n t s  w i t h  d e c r e a s e d  TGFBR1  allelic
expression (p = 0.498; Fisher's Exact Test). A family his-
tory of colorectal cancer in a first or second degree rela-
t i v e  w a s  p r e s e n t  i n  2 9 %  o f  a l l  p a t i e n t s  a n d  w a s
comparable between the two groups (Table 1).
Association of TGFBR1 SNPs with TGFBR1 allele-specific 
expression
Three SNPs in linkage disequilibrium with each other
were strongly associated with TGFBR1 ASE: rs7034462 (p
= 7.2 × 10-4), TGFBR1*6A (p = 1.6 × 10-4) and rs11568785
(p = 1.4 × 10-4) (Table 2). TGFBR1*6A is located within
the coding sequence of exon 1 and the other two SNPs are
located within introns. rs7034462 is located 9.2 kb
upstream of exonn 1 and rs11568785 is located 850 bp
downstream of exonn 5 and 1.18 kb upstream of exonn 6.
These results are consistent with our earlier findings as
each of these SNPs was significantly associated with
TGFBR1 ASE in our original study. For example, in this
study six (54.5%) of the 11 patients with TGFBR1 ASE
carried the TGFBR1*6A allele. In our previous report 14
(48.3%) of the 29 patients with TGFBR1 ASE carried the
TGFBR1*6A allele. This provides additional evidence of a
central role for TGFBR1*6A in colorectal cancer, espe-
cially as it relates to the TGFBR1 ASE phenotype. Studies
are currently in progress to validate the association of
TGFBR1 SNPs with colorectal cancer risk.
Discussion
These findings confirm the relatively high frequency of
the TGFBR1 ASE phenotype in patients with colorectal
cancer. The phenotype frequency among Caucasian
patients included in this study (10.2%) is similar to that of
the Caucasian patients studied in our earlier report
(12.0%)[14]. Intriguingly, Guda et al. did not identify any
individual with the TGFBR1 ASE phenotype among 96
patients with colorectal cancer without any family history
of colorectal cancer[15]. They identified a low (1.9%) fre-
quency of the phenotype among 102 patients with famil-
ial colon neoplasia[15]. Our patient population was not
entirely similar to the patients with sporadic colorectal
cancer reported in the Guda et al. study. The average age
at diagnosis of the patients with sporadic colorectal can-
cer in that study was 69 while the median age at diagnosis
in our study was 60. Also, the proportion of Caucasians
was more than 10% lower in the Guda study (71%) than in
our study (83%).
However, the main difference between these two stud-
ies is the tissue from which DNA and RNA were
extracted. In both our original report[14] and in this
study we used lymphoblastoid cell lines and peripheral
blood lymphocytes whereas Guda et al. extracted DNA
and RNA from the normal-appearing mucosa layer of the
colon from patients with sporadic colorectal cancer[15].
The authors assumed that if TGFBR1 ASE were a driver
of colorectal cancer, the lower expression of one TGFBR1
allele should likely also be evidenced in colon epithelial
cells from affected individuals.
While we agree with this reasoning, it possible that the
TGFBR1 allelic expression ratio in lymphoblastoid cell
lines is not the same as in normal appearing colonic epi-
thelium. We have previously shown that TGFBR1*6A,
one of the SNPs previously associated with the TGFBR1
ASE phenotype[14], is somatically acquired in the normal
appearing colonic epithelium of a small proportion of
patients with colorectal cancer[17]. This provides sup-
port for the notion that either somatically-acquired
mutations or epigenetic changes may affect the TGFBR1
gene in the normal appearing colonic epithelium and may
therefore affect determination of the TGFBR1 ASE phe-
notype. Several recent studies have demonstrated that
genetic alterations within the stroma may have a potent
effect on cancer progression[18]. Hence, another poten-
tial explanation for these differences is altered stromal
TGF-β signaling, which is emerging as a potent modifierPasche et al. Journal of Experimental & Clinical Cancer Research 2010, 29:57
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of cancer susceptibility[19]. Identification of the TGFBR1
ASE phenotype in African American patients suggests
that this phenotype may not be exclusively found in Cau-
casians. Additional studies in various ethnic groups are
warranted.
In summary our results confirm the high frequency of
the TGFBR1 ASE phenotype among patients with col-
orectal cancer and suggest a central role of the TGFBR1
locus in the etiology of this disease.
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Table 1: Demographics and clinical characteristics of patients with and without constitutively decreased TGFBR1 allelic 
expression (TGFBR1 ASE).
All patients TGFBR1 ASE + TGFBR1 ASE -
Age, years No % No % No %
Median age 59.5 64.0 59
Range 35-84 52-77 35-84
Sex
Female 55 46.6 4 3.4 51 43.2
Male 63 53.4 7 5.9 56 47.5
Tumor 
location
Colon 77 65.3 6 5.1 71 60.2
Rectum 40 33.9 5 4.2 35 29.7
B o t h 10 . 8 0010 . 8
Ethnic status
Caucasian 98 83.1 10 8.5 88 7.5
African 
American
14 11.9 1 0.8 13 11.0
Asian 3 2.5 0 0 3 2.5
H i s p a n i c 32 . 5 0032 . 5
Stage at 
diagnosis
Stage 1 11 9.3 1 0.8 10 8.5
Stage 2 30 25.4 5 4.2 25 21.2
Stage 3 44 37.3 1 0.8 43 36.4
Stage 4 33 28.0 4 3.4 29 24.6
Family history
No 76 64.4 7 5.9 69 58.5
Yes 34 28.8 3 2.5 31 26.3
Unknown 8 6.8 1 0.8 7 5.9Pasche et al. Journal of Experimental & Clinical Cancer Research 2010, 29:57
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Table 2: Association of TGFBR1 SNPs with constitutively decreased TGFBR1 allelic expression (TGFBR1 ASE).
Frequency Allele 2
SNP ASE < 0.67 or > 1.5 1.5 > ASE > 0.67 P OR
rs4742761 0.14 0.25 0.38 0.5
rs2416666 0.19 0.19 0.98 1.0
rs7874183 0.13 0.28 0.20 0.4
rs7034462 0.31 0.05 7.2 × 10-4 8.3
rs10819634 0.06 0.26 0.08 0.2
rs1888223 0.50 0.30 0.11 2.3
9A/6A 0.31 0.04 1.6 × 10-4 10.9
rs10988705 0.00 0.04 0.42 n/a
rs6478974 0.50 0.47 0.82 1.1
rs10739778 0.38 0.36 0.89 1.1
rs2026811 0.25 0.32 0.57 0.7
rs10512263 0.00 0.11 0.16 n/a
rs11568785 0.25 0.02 1.4 × 10-4 16.0
rs334348 0.31 0.39 0.55 0.7
rs7871490 0.50 0.46 0.77 1.2
rs334349 0.25 0.43 0.19 0.5
rs7850895 0.07 0.06 0.87 1.2
rs1590 0.25 0.39 0.28 0.5
rs1626340 0.25 0.32 0.57 0.7Pasche et al. Journal of Experimental & Clinical Cancer Research 2010, 29:57
http://www.jeccr.com/content/29/1/57
Page 6 of 6
References
1. Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I: An update on the 
genetics of colorectal cancer.  Human Molecular Genetics 2004, 
13:R177-R185.
2. de la Chapelle A: Genetic predisposition to colorectal cancer.  Nat Rev 
Cancer 2004, 4:769-780.
3. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, 
et al.: Meta-analysis of genome-wide association data identifies four 
new susceptibility loci for colorectal cancer.  Nat Genet 2008, 
40:1426-1435.
4. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan 
A, et al.: A genome-wide association study shows that common alleles 
of SMAD7 influence colorectal cancer risk.  Nat Genet 2007, 
39:1315-1317.
5. Tenesa A, Dunlop MG: New insights into the aetiology of colorectal 
cancer from genome-wide association studies.  Nat Rev Genet 2009, 
10:353-358.
6. Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit 
K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VV: Type I 
transforming growth factor beta receptor maps to 9q22 and exhibits a 
polymorphism and a rare variant within a polyalanine tract.  Cancer Res 
1998, 58:2727-2732.
7. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang 
D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, 
Massagué J, Offit K: T beta R-I(6A) is a candidate tumor susceptibility 
allele.  Cancer Res 1999, 59:5678-5682.
8. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, 
Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, 
Dolan ME, Vokes EE, Lane WS, Huang CC, Caldes T, Di Cristofano A, 
Hampel H, Nilsson I, von Heijne G, Fodde R, Murty VV, de la Chapelle A, 
Weghorst CM: Somatic Acquisition and Signaling of TGFBR1*6A in 
Cancer.  JAMA: The Journal of the American Medical Association 2005, 
294:1634-1646.
9. Zhang HT, Zhao J, Zheng SY, Chen XF: Is TGFBR1*6A Really Associated 
With Increased Risk of Cancer?  J Clin Oncol 2005, 23:7743-7744.
10. Pasche B, Kaklamani VG, Hou N, Young T, Rademaker A, Peterlongo P, Ellis 
N, Offit K, Caldes T, Reiss M, Zheng T: TGFBR1*6A and Cancer: A Meta-
Analysis of 12 Case-Control Studies.  J Clin Oncol 2004, 22:756-758.
11. Skoglund y, Song B, Dalen J, Dedorson S, Edler D, Hjern F, Holm J, 
Lenander C, Lindforss U, Lundqvist N, Olivecrona H, Olsson L, Påhlman L, 
Rutegård J, Smedh K, Törnqvist A, Houlston RS, Lindblom A: Lack of an 
Association between the TGFBR1*6A Variant and Colorectal Cancer 
Risk.  Clinical Cancer Research 2007, 13:3748-3752.
12. Zeng Q, Phukan S, Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang 
GY, Huang CC, Valle L, Di Cristofano A, de la Chapelle A, Pasche B: Tgfbr1 
Haploinsufficiency Is a Potent Modifier of Colorectal Cancer 
Development.  Cancer Res 2009, 69:678-686.
13. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, 
Zborowska E, Kinzler KW, Vogelstein B: Inactivation of the type II TGF-
beta receptor in colon cancer cells with microsatellite instability.  
Science 1995, 268:1336-1338.
14. Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng 
Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle 
A: Germline allele-specific expression of TGFBR1 confers an increased 
risk of colorectal cancer.  Science 2008, 321:1361-1365.
15. Guda K, Natale L, Lutterbaugh J, Wiesner GL, Lewis S, Tanner SM, Tomsic J, 
Valle L, de la Chapelle A, Elston RC, Willis J, Markowitz SD: Infrequent 
Detection of Germline Allele-Specific expression of TGFBR1 in 
Lymphoblasts and Tissues of Colon Cancer Patients.  Cancer Res 2009, 
69:4959-4961.
16. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, 
Ahsan H, Mantzoros C, Pasche B: Variants of the adiponectin (ADIPOQ) 
and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer 
risk.  JAMA 2008, 300:1523-1531.
17. Bian Y, Knobloch TJ, Sadim M, Kaklamani V, Raji A, Yang GY, Weghorst CM, 
Pasche B: Somatic acquisition of TGFBR1*6A by epithelial and stromal 
cells during head and neck and colon cancer development.  Human 
Molecular Genetics 2007, 16:3128-3135.
18. Eng C, Leone G, Orloff MS, Ostrowski MC: Genomic Alterations in Tumor 
Stroma.  Cancer Res 2009, 69:6759-6764.
19. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, 
Washington MK, Neilson EG, Moses HL: TGF-{beta} Signaling in 
Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia.  
Science 2004, 303:848-851.
doi: 10.1186/1756-9966-29-57
Cite this article as: Pasche et al., Constitutively decreased TGFBR1 allelic 
expression is a common finding in colorectal cancer and is associated with 
three TGFBR1 SNPs Journal of Experimental & Clinical Cancer Research 2010, 
29:57
Received: 21 April 2010 Accepted: 25 May 2010 
Published: 25 May 2010
This article is available from: http://www.jeccr.com/content/29/1/57 © 2010 Pasche et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:57